BAX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BA

Mkt Cap

$13.07B

Volume

3.33M

Next Earnings

October 29th

Loading chart

BA

BAXBaxter International Inc.

BAX

Pay with—

Available Balance0.00

BA

Mkt Cap

$13.07B

Volume

3.33M

Next Earnings

October 29th

Chart Financials Earnings News About Dividends Insider Filings

Are Investors Undervaluing Baxter International (BAX) Right Now?Zacks highlights two Medical-Products stocks with strong value characteristics: Baxter International (BAX) and Zimmer Biomet (ZBH), both holding Zacks Rank #2 (Buy) ratings and Value grade A. Both stocks trade at attractive valuations compared to industry averages across multiple metrics including P/E, PEG, P/B, and P/S ratios, suggesting they are currently undervalued with strong earnings outlooks.Zacks Investment Research · Oct 6, 2026

Is Baxter International (BAX) Stock Outpacing Its Medical Peers This Year?Baxter International (BAX) has significantly outperformed the medical sector year-to-date, returning 26.7% compared to the sector's -0.2% average loss. The stock holds a Zacks Rank #2 (Buy) with improving analyst sentiment, as consensus earnings estimates have increased 6.5% in the past quarter. BAX is outperforming its Medical-Products industry peers, which have declined 22.4% on average.Zacks Investment Research · Oct 6, 2026

Why Investors Need to Take Advantage of These 2 Medical Stocks NowThe article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies stocks likely to beat quarterly earnings estimates by comparing the most recent analyst estimates against consensus estimates. When combined with a Zacks Rank of #3 or better, stocks with positive ESP have historically produced 70% positive surprises and 28.3% average annual returns. The article highlights Eli Lilly and Baxter International as examples of stocks with positive ESP ahead of their October 29, 2026 earnings releases.Zacks Investment Research · Sep 29, 2026

Veterinary Ophthalmology Equipment Market by Product, Animal Type, Application, End User, Region Report Forecasts Market to Reach USD 0.83 Billion by 2031, Growing at a 7.7% CAGRThe global veterinary ophthalmology equipment market is expected to grow from USD 0.57 billion in 2026 to USD 0.83 billion by 2031, at a 7.7% CAGR. Growth is driven by rising pet ownership, increased prevalence of animal eye diseases, and adoption of advanced diagnostic and surgical technologies. Treatment applications and surgical equipment segments are leading growth, with Asia Pacific emerging as the fastest-growing region.GlobeNewswire Inc. · Sep 24, 2026

Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS InsiderThe global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma supply dependency and a 100% U.S. tariff on imported IVIG products implemented in October 2025 pose significant constraints. North America leads the market, while Asia-Pacific shows the fastest growth.GlobeNewswire Inc. · Sep 10, 2026

Drug Reconstitution Systems Market Trends, Shares and Growth Opportunities Worldwide 2026-2035 Featuring Profiles of Baxter, ICU Medical, B. Braun, Vetter Pharma, Nipro, SCHOTT-KAISHAThe global drug reconstitution systems market is expected to grow at a 7.0% CAGR from $5.9 billion in 2026 to $10.8 billion by 2035, driven by expanding biologic and biosimilar pipelines, increasing demand for safer drug delivery systems, and the shift toward home healthcare and self-administered therapies. Cartridges lead the market at 50% revenue share, while prefilled syringes are expected to grow faster. Asia-Pacific is projected to achieve the fastest regional growth.GlobeNewswire Inc. · Sep 7, 2026

Why Baxter International Stock Skyrocketed by 19% This WeekBaxter International's stock surged 19% following strong second-quarter earnings that beat analyst expectations. The company reported $2.96 billion in sales (5% YoY growth) and raised full-year guidance for both revenue growth (3-4%) and adjusted EPS ($1.95-$2.15), citing strong performance across both product categories and geographic regions.The Motley Fool · Aug 1, 2026

Global Human Fibrinogen Concentrate Market Size/Share Worth USD 2.78 Billion by 2035 at a 11.3% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)The global human fibrinogen concentrate market, valued at USD 0.95 billion in 2025, is projected to grow at a 11.3% CAGR to reach USD 2.78 billion by 2035. Growth is driven by increasing bleeding disorders, surgical procedures, and demand for effective hemostatic therapies. Lyophilized forms dominate the market, with hospitals being the primary end-users. Asia Pacific is expected to experience the highest growth rate.GlobeNewswire Inc. · Jul 1, 2026

Becton Dickinson at 13x Earnings: MedTech’s Most Mispriced CompounderBecton Dickinson (BDX) trades at a 13x forward P/E multiple, representing a significant discount to medtech peers despite strong fundamentals including 60% U.S. infusion pump market share, 90%+ recurring revenue, and record 25% adjusted operating margins. The post-spin-off transition year narrative masks an emerging pure-play MedTech company with billion-dollar growth platforms in GLP-1 drug delivery and connected care, supported by $4 billion in fresh capital deployment and ongoing margin expansion targeting 26%+ territory.Investing.com · May 7, 2026

Robotic Pharmacy Prescription Market Research and Global Forecast Report 2025-2032The global robotic pharmacy prescription market is experiencing significant growth, expanding from USD 214.16 million in 2025 to USD 237.65 million in 2026, with a projected CAGR of 9.18% through 2032, reaching USD 396.21 million. The market is driven by automation adoption for medication safety and efficiency, workforce transformation toward clinical roles, and bundled solution procurement strategies across hospitals, clinics, and long-term care facilities.GlobeNewswire Inc. · Apr 9, 2026

to start trading

BA

BAXBaxter International Inc.

BAX

Pay with—

Available Balance0.00

Your PositionYou don't own any BAX yet.

Related Tickers

Earnings

Dividends

Last · Aug 28Quarterly

Amount$0.0100

Yield0.16%

Annual$0.0400